Likely Impact of Net Price Referencing on European Markets.

CONCLUSION Using data from PRICENTRICTM, we collected net and list ex-factory prices for Avastin, Caprelsa and Vidaza across EU-28. Countries that do not use formal IRP as a price setting mechanism were excluded from the analysis, countries that consider price reviews were included. In the case of Germany, the negotiated AMNOG price minus mandatory rebates was used, for Italy the AIFA price and Spain list price less 7.5% rebate. Projected prices were calculated using country IRP rules and exchange rates from the European Central Bank. The current approved prices were compared to the likely projected prices. The analysis investigated two key areas: 1. Countries impacted and 2. Potential price impact.